The Medicines Company v. Hospira (July 11, 2016)

This opinion is interesting because it provides a meta-analysis of on-sale bar cases and also provides a methodology for determination of an on-sale bar.  The conclusion the CAFC draws is:

The CAFC punted, however, on the issue of “experimental use.”  Here is a relevant excerpt: